MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

All NewsJune 12, 2026

MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT